Pfizer
No price chart data available for 1D timeframe.
Rating
Why Price Moved
Shares are trading lower after Pfizer secured Blac...
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehe...
Latest News
2 days ago · fool.com
5 Dividend Stocks With High Yields That Are Safer Than You Might ThinkA high yield is a sign that investors are worried about a business, but sometimes that concern is overwrought.
2 days ago · fool.com
Novo Nordisk vs. Pfizer: Does a Weight Loss or Cancer Focused Pharma Stock Make a Better Buy for 2027?Novo Nordisk A/S maintains a leading position in the high-growth obesity and diabetes treatment markets. Pfizer offers a highly diversified product portfolio and significant free cash flow generation.
2 days ago · fool.com
Pfizer's 5.9% Yield vs. AbbVie's 53-Year Dividend Streak: Which Stock Is the Better Buy?Pfizer offers one of the highest yields in healthcare. AbbVie is a Dividend King with solid growth prospects.
3 days ago · fool.com
Pfizer Just Raised Its 2026 Revenue Forecast by $1.5 Billion. Is the High-Yield Stock a Buy Right Now?Investors are downbeat on Pfizer, at least in part due to concerns about innovation and patent expirations. The company continues to invest in new drugs, but innovation can't be scheduled.
3 days ago · zacks.com
Pfizer Stock Down 6% Post Q3 Earnings: Time to Buy, Hold or Exit?PFE shares fell despite the company beating Q3 estimates and raising guidance. Explore its growth drivers, pipeline potential, patent risks & attractive valuation.
4 days ago · seekingalpha.com
Pfizer: $1.5bn Of Blackstone Funding Doesn't Make Berobenatide A Winning Obesity DrugPfizer partners with Blackstone, securing up to $1.5bn in funding for berobenatide, a potential first-in-class monthly GLP-1 agonist for obesity. PFE faces stagnant revenues, heavy debt, and looming patent expiries on key drugs, making GLP-1 success critical for future growth. Berobenatide offers monthly dosing and potential manufacturing cost advantages, but safety and efficacy data have notable gaps versus established competitors.
4 days ago · zacks.com
Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity ProgramPFE gets up to $1.5 billion from Blackstone to fund berobenatide's development through 2028, retaining full control of the obesity program.
4 days ago · barrons.com
Why Pfizer Is Tapping Private Equity to Back Its Once-Monthly Weight-Loss DrugBlackstone Life Sciences agrees to pay $1.5 billion in development costs for Pfizer's berobenatide through 2028 in exchange for milestone-based payments.
5 days ago · wsj.com
Pfizer Signs $1.5 Billion Deal With Blackstone to Fund Weight-Loss-Drug DevelopmentThe investment is set to cover development costs for berobenatide, an investigational drug being studied for chronic weight management and obesity-related conditions.
5 days ago · reuters.com
Pfizer secures up to $1.5 billion from Blackstone for obesity drug developmentPfizer secures up to $1.5 billion from Blackstone for obesity drug development
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove PFE